← Leaderboards
Warren Phipps
Fred Hutchinson Cancer Center
$6,635,898
Attributed
$13,912,087
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2011–25$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,426,524 · 9
By mechanism
R01$8,952,662 · 3
U54$2,514,437 · 1
D43$2,315,157 · 2
U01$1,535,738 · 1
K23$714,071 · 1
R21$394,459 · 1
Top collaborators
- Edus Houston Warren18 shared
- Jackson Orem15 shared
- Joshua Tisdell Schiffer6 shared
- Corey Casper4 shared
- Jim Boonyaratanakornkit2 shared
- Ethel Cesarman2 shared
- Andrew Mcguire2 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Edus Houston Warren$15,290,791
- Jackson Orem$1,717,870
- Joshua Tisdell Schiffer$7,320,811
- Andrew McGuire$8,683,437
- Jim Boonyaratanakornkit$2,850,119
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsUgandaKaposi SarcomaViralInstitutesPersonsResponseHuman Herpesvirus 8Antiretroviral TherapyAfrica South Of The SaharaImmune ResponseVirusHiv InfectionsFred Hutchinson Cancer Research CenterCancer EtiologyTumorSamplingCohortEnrollmentTreatment ResponseGenesBaseAids Related CancerChemotherapy
Grant awards (39)
Defining Critical Sites of Vulnerability and Correlates of Protection to Kaposi Sarcoma Associated Herpesvirus to Inform Vaccine Design$768,047
U01 · FY2025 · CA
Training in Cancer Genomics and Genomic Data Science$230,816
D43 · FY2025 · CA
Defining Critical Sites of Vulnerability and Correlates of Protection to Kaposi Sarcoma Associated Herpesvirus to Inform Vaccine Design$767,691
U01 · FY2024 · CA
Characterizing determinants of primary KSHV infection among children and adolescents in Uganda$588,810
R01 · FY2023 · CA · contact PI
Dissecting the Kaposi Sarcoma Tumor Microenvironment at the Single Cell Level$547,525
R01 · FY2023 · CA · contact PI
Building independent research leaders in HIV-associated malignancies in Uganda$298,787
D43 · FY2023 · TW · contact PI
Dissecting the Kaposi Sarcoma Tumor Microenvironment at the Single Cell Level$634,763
R01 · FY2022 · CA · contact PI
Characterizing determinants of primary KSHV infection among children and adolescents in Uganda$563,827
R01 · FY2022 · CA · contact PI
Building independent research leaders in HIV-associated malignancies in Uganda$299,012
D43 · FY2022 · TW · contact PI
Dissecting the Kaposi Sarcoma Tumor Microenvironment at the Single Cell Level$637,815
R01 · FY2021 · CA · contact PI
Characterizing determinants of primary KSHV infection among children and adolescents in Uganda$582,929
R01 · FY2021 · CA · contact PI
Building independent research leaders in HIV-associated malignancies in Uganda$299,988
D43 · FY2021 · TW · contact PI
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa$218,186
R01 · FY2021 · CA
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa$190,771
R01 · FY2021 · CA
Dissecting the Kaposi Sarcoma Tumor Microenvironment at the Single Cell Level$175,086
R01 · FY2021 · CA · contact PI
Characterizing determinants of primary KSHV infection among children and adolescents in Uganda$1
R01 · FY2021 · CA · contact PI
Dissecting the Kaposi Sarcoma Tumor Microenvironment at the Single Cell Level$637,486
R01 · FY2020 · CA · contact PI
Characterizing determinants of primary KSHV infection among children and adolescents in Uganda$566,520
R01 · FY2020 · CA · contact PI
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa$417,390
R01 · FY2020 · CA
Building independent research leaders in HIV-associated malignancies in Uganda$298,884
D43 · FY2020 · TW · contact PI
Dissecting the Kaposi Sarcoma Tumor Microenvironment at the Single Cell Level$658,549
R01 · FY2019 · CA · contact PI
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa$598,405
R01 · FY2019 · CA
Characterizing determinants of primary KSHV infection among children and adolescents in Uganda$566,361
R01 · FY2019 · CA · contact PI
Biologic Determinants of the Natural History of AIDS-Defining Cancers in Uganda$295,105
U54 · FY2019 · CA · contact PI
Building independent research leaders in HIV-associated malignancies in Uganda$281,310
D43 · FY2019 · TW · contact PI
Biologic Determinants of the Natural History of AIDS-Defining Cancers in Uganda$737,761
U54 · FY2018 · CA · contact PI
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa$723,817
R01 · FY2018 · CA
Expanding independent research capacity in HIV-associated malignancies in Uganda$303,180
D43 · FY2018 · TW · contact PI
Defining the Cellular Oncogenome of Kaposi Sarcoma$171,135
R21 · FY2018 · CA
Biologic Determinants of the Natural History of AIDS-Defining Cancers in Uganda$738,290
U54 · FY2017 · CA · contact PI
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa$644,421
R01 · FY2017 · CA
Expanding independent research capacity in HIV-associated malignancies in Uganda$303,180
D43 · FY2017 · TW · contact PI
Defining the Cellular Oncogenome of Kaposi Sarcoma$223,324
R21 · FY2017 · CA
Biologic Determinants of the Natural History of AIDS-Defining Cancers in Uganda$743,281
U54 · FY2016 · CA · contact PI
Human Herpesvirus-8 Replication and Kaposi Sarcoma Response to Treatment$142,035
K23 · FY2015 · CA · contact PI
Human Herpesvirus-8 Replication and Kaposi Sarcoma Response to Treatment$144,967
K23 · FY2014 · CA · contact PI
Human Herpesvirus-8 Replication and Kaposi Sarcoma Response to Treatment$142,429
K23 · FY2013 · CA · contact PI
Human Herpesvirus-8 Replication and Kaposi Sarcoma Response to Treatment$143,339
K23 · FY2012 · CA · contact PI
Human Herpesvirus-8 Replication and Kaposi Sarcoma Response to Treatment$141,301
K23 · FY2011 · CA · contact PI